Early anemia in diabetic nephropathy;Korai anaemia diabeteses nephropathiában

Orvosi Hetilap

Volumn 146, Issue 9, 2005, Pages 397-401

  Nagy, Judit ^a,b   Kiss, István ^b   Wittmann, István ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

^b I Belgyógyászati Osztály ^*  (Hungary)

Author keywords

Anemia; Cardiovascular diseases; Diabetes mellitus; Diabetic nephropathy; Erythropoietin

Indexed keywords

ERYTHROPOIETIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; CARDIOVASCULAR DISEASE; DIABETIC NEUROPATHY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; PROTEIN URINE LEVEL; BIOSYNTHESIS; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; DIABETIC NEPHROPATHY; IRON DEFICIENCY ANEMIA; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; REVIEW; TIME; URINE;

ANEMIA, HYPOCHROMIC; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; EPOETIN ALFA; ERYTHROPOIETIN; HEART FAILURE, CONGESTIVE; HUMANS; KIDNEY FAILURE, CHRONIC; RANDOMIZED CONTROLLED TRIALS; TIME FACTORS;

EID: 18744391641     PISSN: 00306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Akimoto, T., Kusano, E., Inaba, T. és mtsai: Erythropoietin regulates vascular smooth muscle cell apoptosis by a phosphatidylinositol 3 kinase-dependent pathway. Kidney Int., 2000, 58, 269-282.
2. Amos, A. F., McCarty, D. J., Zimmer, P.: The rising global burden of diabetes and its complications; estimates and projections to the year 2010. Diabet. Med., 1997, 14 (Suppl. 5.), S7-S85.
3. Astor, B. C., Muntner, P., Levin, A. és mtsai: Association of kidney function with anaemia. Arch. Inter. Med., 2002, 162, 1401-0408.
4. Benz, R. L., Pressman, M. R., Hovick, E. T. és mtsai: A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorder, and daytime sleepiness in hemodialysis patients (the SLEEPO study). Am. J. Kidney Dis., 1999, 34, 1089-1095.
5. Berman, D. H., Friedman, E. A.: Partial absorption of hard exudates in patients with diabetic end-stage renal disease and severe anemia after treatment with erythropoietin. Retina, 1994, 14, 1-5.
6. Besarab, A., Ross, R. P., Nasca, T. J.: The use of recombinant human erythropoietin in predialysis patients. Curr. Opin. Nephrol. Hypertens., 1995, 4, 155-161.
7. Bilous, R.: Anaemia - a diabetologist's dilemma? Acta Diabetol., 2002, 39, S15-S19.
8. Bosman, D. R. Winkler, A., Marsden J. és mtsai: Anemia with erythropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care, 2001, 24, 495-499.
9. Carlini, R. G., Alonzo, E. J., Dominguez, J. és mtsai: Effect of recombinant human erythropoietin on endothelial cell apoptosis. Kidney. Int., 1999, 55, 546-553.
10. European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. Nephrol. Dial. Transplant., 1999, 14 (Suppl. 5.), 1-50.
11. Foley, R. N., Parfrey, P. S., Sarnak, M. J.: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am. J. Kidney Dis., 1998, 32 (Suppl. 3.), S112-S119.
12. Foley, R. N.: Anaemia and the heart: what's new in 2003? Nephrol. Dial. Transplant., 2003, 18 (Suppl. 8.), viii13-viii16.
13. Gilbertson, D., Li, S., Murray, A. M., Herzog, C.A, és mtsai: Competing risks of death vs ESRD in Medicare beneficiaries age 65+ with chronic kidney disease, CHF and anemia. J. Am. Soc. Nephrol., 2002, 13, SA848 (Abstract).
14. Grimm, G., Stockenhuber, P., Schneeweiss, B. és mtsai: Improvement of brain function in hemodialysis patients treated with erythropoietin. Kidney Int., 1990, 38, 480-486.
15. Grune, T., Sommerburg, O., Siems, W. G.: Oxidative stress in anaemia. Clin. Nephrol., 2000, 53 (Suppl 1.), S18-S22.
16. Hayashi, T., Suzuki, A., Shoji, T. és mtsai: Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am. J. Kidney Dis., 2000, 35, 250-256.
17. Hsu, C., McCulloch, C., Curhan, G.: Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J. Am. Soc. Nephrol., 2002, 13, 504-510.
18. Inomata. S., Itoh, M., Imai, H. és mtsai: Serum levels of erythropoietin as a novel marker reflecting the severity of diabetic nephropathy. Nephron, 1997, 75, 426-430.
19. Ishimitsu, T., Ono, H., Sugiyama, M. és mtsai: Successful erythropoietin treatment for severe anemia in nephrotic syndrome without renal dysfunction. Nephron, 1996, 74, 607-610.
20. Ishimura, E., Nishizawa, Y., Okuno, S. és mtsai: Diabetes mellitus increases the severity of anemia in non-dialyzed patients with renal failure. J. Nephrol., 2001, 11, 83-86.
21. Kazmi, W.H., Kausz, A.T., Khan, S. és mtsai: Anemia: an early complication of chronic renal insufficiency. Am. J. Kidney. Dis., 2001, 38, 803-812.
22. Kojima, K., Totsuka, Y.: Anemia due to reduced serum erythropoietin concentration in non-uremic diabetic patients. Diabetes Res. Clin. Pract., 1995, 27 (Suppl.), 229-233.
23. Kuriyama, S., Tomonari, H., Yoshida, H. és mtsai: Reversal of anaemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron, 1997, 77, 176-185.
24. Laville, M.: New strategies in anaemia management: ACORD (Anaemia CORrection in Diabetes) trial. Acta Diabetol., 2004, 41, S18-S22.
25. Levin, A., Djurdjev, O., Barrett, B. és mtsai: Cardiovascular disease in patients with chronic kidney disease: Getting to the heart of the matter. Am. J. Kidney Dis. 2001, 38, 1398-1407.
26. Levin, A., Singer, J., Thompson, C.R. és mtsai: Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention. Am. J. Kidney Dis., 1996, 27, 347-354.
27. Macdougall, I. C.: CREATE: new strategies for early anaemia management in renal insufficiency. Nephrol. Dial. Transplant., 2003, 18 (Suppl. 2.), ii13-ii16.
28. Mancini, D. M., Katz, S. D., Lang, C. C. és mtsai: Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation, 2003, 107, 294-299.
29. McMahon, L. P., Mason, K., Skinner, S. L. és mtsai: Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. Nephrol. Dial. Transplant., 2000, 15, 1425-1430.
30. McMahon, L. P., McKenna, M. J., Sangkabutra, T. és mtsai: Physical performance and associated electrolyte changes after haemoglobin normalization: A comparative study in haemodialysis patients. Nephrol. Dial. Transplant., 1999, 14, 1182-1187.
31. More-no. F., Sanz-Guajardo, D., Lopez-Gomez, J. M. és mtsai: Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients: Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology. J. Am. Soc. Nephrol. 2000, 11, 335-342.
32. Nagy, J., Wittmann I., Kammerer L.: Veseszövodmények diabetesben. In Diabetes mellitus. Szerk.: Halmos T., Jermendy Gy. Medicina, Budapest, 3. kiadás, 2000, 450-478. old.
33. Pereira, A. A., Sarnak, M. J.: Anemia as a risk factor for cardiovascular disease. Kidney Int., 2003, 64 (Suppl. 87.), S32-S39.
34. Portoles, J., Torralbo, A., Martin, P. és mtsai: Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am. J. Kidney Dis., 1997, 29, 541-548.
35. Ritz, E.: Advances in nephrology: successes and lessons learnt from diabetes mellitus. Nephrol. Dial. Transplant., 2001, 16 (Suppl. 7.), 46-50.
36. Roger, S. D., McMahon, L. P., Clarkson, A. és mtsai: Effects of early and late intervention with epoetin on left ventricular mass among patients with chronic kedney disease (stage 3 or 4): results of a randomized clinical trial. J. Am. Soc. Nephrol., 2004, 15, 148-156.
37. Rossert, J., McClellan, W. M., Roger, S. D. és mtsai: Epoetin treatment: what are the arguments to expect a beneficial effect on renal disease progression? Nephrol. Dial. Transplant., 2002, 17, 359-362.
38. Roth, D., Smith, R. D., Schulman, G. és mtsai: Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. Am. J. Kidney Dis., 1994, 24, 777-784.
39. Shuvaev, V. V., Fukii, J., Kawasaki, Y és mtsai: Glycation of apolipoprotein E impairs its binding to heparin: Identification of the major glycations site. Biochim. Biophys. Acta, 1999, 30, 296-308.
40. Silva, M., Grillot, D., Benito, A. és mtsai: Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bel-XL and Bcl-2. Blood, 1996, 88, 1576-1582.
41. Silverberg, D.: Outcomes of anaemia management in renal insufficiency and cardiac disease. Nephrol. Dial Transplant., 2003, 18 (Suppl. 2.), ii7-ii12.
42. Siverberg, D, Wexle., D., Blum, M. és mtsai: The cardio-renal anaemia syndrome: does it exist? Nephrol. Dial. Transplant., 2003, 18 (Suppl. 8.), wiii7-viii12.
43. Stenvinkel, P.: Anaemia and inflammation: what are the implications for the nephrologist? Nephrol. Dial. Transplant., 2003, 18 (Suppl. 8.), viii17-viii22.
44. Stevens, P. E., O'Donoghue, D. J., Lameire, N. R.: Anaemia in patients with diabetes: unrecognised, undetected and untreated? Curr. Med. Res. Opin., 2003, 19, 395-401.
45. Thomas, M., C., MacIsaac, R., J., Tsalamandris, C. és mtsai: The burden of anaemia in type 2 diabetes and the role of nephropathy: a cross-sectional audit. Nephrol. Dial. Transplant. 2004, 19, 1792-1797.
46. Update on the European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure II. Nephrol. Dial. Transplant., 2004, in print.
47. Vaziri, N. D., Kaupke, C. J., Barton, C. H. és mtsai: Plasma concentration and the urinary excretion of erythropoietin in adult nephrotic syndrome. Am. J. Med., 1992, 92, 35-40.
48. Wada, Y., Matsuoka, H., Tamai, O. és mtsai: Erythropoietin impairs endothelium-dependent vasorelaxation through cyclooxygenase-dependent mechanisms in humans. Am. J. Hypertens., 1999, 12, 980-987.
49. Wentenfelder, C., Biddle, D. L., Baranowski, R. L.: Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int., 1999, 55, 808-820.
50. Winkler, A. S., Marsden, J., Chaudhuri, K. R. és mtsai: Erythropoietin depletion and anaemia in diabetes mellitus. Diabet. Med., 1999, 16, 813-819.